VAX-31 has the potential to be "a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards," he added. The company is also developing a 24-valent pneumococcal ...

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot. Merck's Vaxneuvance ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial ...

Last week, Vaxcyte reported top-line results from the mid-stage study that evaluated its 24-valent PCV VAX-24 against Pfizer’s PFE Prevnar 20. The Pfizer vaccine is approved for preventing ...

The CDC’s ACIP updated guidance on pneumococcal vaccination, recommending a single dose of PCV for all adults aged 50 years and older.

That's because the positive data reinforces that VAX-24 as a pneumococcal vaccine candidate may end up being better than that of Pfizer's (PFE) Prevnar 20 [PCV]. This tees up the company to ...

According to a press release, from a safety perspective, VAX-24 was "well-tolerated and demonstrated a safety and tolerability profile similar to Prevnar 20 - Prevnar 20 is part of Pharma giant ...

tolerability and immunogenicity of VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20 ...